Drug Profile


Alternative Names: KPS-0373; S-0373; Thyrotropin-releasing hormone derivative; TSH derivative

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Shionogi
  • Developer Kissei Pharmaceutical; Shionogi
  • Class
  • Mechanism of Action Thyrotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Spinocerebellar degeneration
  • Discontinued Parkinson's disease

Most Recent Events

  • 11 Nov 2016 Kissei Pharmaceutical initiates a phase III confirmatory trial for Spinocerebellar degeneration in Japan (NCT02889302)
  • 31 Aug 2016 Kissei Pharmaceutical plans a phase III confirmatory trial for Spinocerebellar degeneration in Japan (NCT02889302)
  • 10 Jun 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top